大分割辅助放疗对淋巴结阳性乳腺癌患者有效:基于人群的分析
该研究基于前瞻性省级数据库,纳入1998至2010年接受治愈性乳房/胸壁及区域淋巴结放疗的5487例淋巴结阳性乳腺癌患者(大分割4006例,常规分割1481例),中位随访12.7年。多变量分析和2:1匹配比较均显示,大分割与常规分割在10年局部区域无复发生存、远处无复发生存和乳腺癌特异性生存上无统计学显著差异,高风险亚组亦然。
要点
- 大分割放疗(40-42.5 Gy/16次)与常规分割(50-50.4 Gy/25-28次)的乳腺癌特异性结局无显著差异。
- 多变量分析10年LRRFS、DRFS、BCSS的HR均无统计学意义。
- 高风险亚组(3级、ER-/HER2-、HER2+、≥4枚阳性淋巴结)亦无统计学差异。
核心结论
- 大分割放疗为接受区域淋巴结放疗的I至III期乳腺癌患者提供了与常规分割相似的有效选择。
研究设计与样本
- 基于前瞻性省级数据库的队列研究,纳入1998至2010年接受治愈性乳房/胸壁及区域淋巴结放疗的淋巴结阳性乳腺癌患者5487例(大分割4006例,常规分割1481例)。
- 中位年龄55岁,中位随访12.7年,采用多变量分析和2:1病例匹配比较大分割与常规分割。
主要发现
- 高风险亚组(3级、ER-/HER2-、HER2+、≥4枚阳性淋巴结)的乳腺癌特异性结局无统计学差异。
临床怎么用
- 对于淋巴结阳性乳腺癌需区域淋巴结放疗的患者,大分割放疗可作为有效选项。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study evaluated long-term, population-based, breast cancer-specific outcomes in patients treated with radiation therapy (RT) to the breast/chest wall plus regional nodes using hypofractionated (HF) (40-42.5 Gy/16 fractions) versus conventionally fractionated (CF) regimens (50-50.4 Gy/25-28 fractions). METHODS AND MATERIALS: A prospective provincial database was used to identify patients with lymph node-positive breast cancer treated with curative-intent breast/chest wall + regional nodal RT from 1998 to 2010. The effect of RT fractionation on locoregional recurrence-free survival (LRRFS), distant recurrence-free survival (DRFS), and breast cancer-specific survival (BCSS) was assessed for the entire cohort and for high-risk subgroups: grade 3, ER-/HER2-, HER2+, and ≥4 positive nodes. Multivariable analysis and 2:1 case-match comparison of HF versus CF were also performed. RESULTS: A total of 5487 patients met the inclusion criteria (4006 HF and 1481 CF). Median age was 55 years, and median follow-up was 12.7 years. On multivariable analysis, no statistically significant differences were identified in 10-year LRRFS (hazard ratio [HR] 0.87; 95% confidence interval [CI], 0.59-1.27; P = .46), DRFS (HR 0.90; 95% CI, 0.76-1.06; P = .19), or BCSS (HR 0.92; 95% CI, 0.76-1.10; P = .36) between the HF and CF cohorts. There was no statistical difference in breast cancer-specific outcomes in the high-risk subgroups. On analysis of 2962 HF cases matched to 1481 CF controls, no statistical difference was observed in LRRFS (HR 0.98; 95% CI, 0.71-1.33; P = .87), DRFS (HR 0.97; 95% CI, 0.85-1.11; P = .68), or BCSS (HR 1.00; 95% CI, 0.87-1.16; P = .92). CONCLUSIONS: This large, population-based analysis with long-term follow-up after locoregional RT demonstrated that modest HF provides similar breast cancer-specific outcomes compared with CF. HF is an effective option for patients with stage I to III breast cancer receiving nodal RT.
引用
- Koulis TA, Nichol AM, Truong PT, et al. Hypofractionated Adjuvant Radiation Therapy Is Effective for Patients With Lymph Node-Positive Breast Cancer: A Population-Based Analysis. Int J Radiat Oncol Biol Phys. 2020. PMID: 32721421. doi:10.1016/j.ijrobp.2020.07.2313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。